Title: COVID-19 in Latin America: Contrasting phylodynamic inference with

epidemiological surveillance.

Running title: Phylodynamic analysis of COVID-19 in Latin America

Authors: Diana M. Rojas-Gallardo,[1] Sandra C. Garzón-Castaño,[1](https://orcid.org/0000-0002-9547-

967X), Natalia Millán[2], Erika V. Jiménez-Posada[4, (http://orcid.org/0000-0002-3737-9427)], Jaime A.

Cardona-Ospina.[1,2,3,4* (https://orcid.org/0000-0003-3996-2293)]

Affiliations: [1]Grupo de Investigación Biomedicina, Facultad de Medicina, Fundación

Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia. [2]Semillero de

Investigación en Infecciones Emergentes y Medicina Tropical, SIEM, Fundación

Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia, [3]Public Health and

Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira,

Pereira, Risaralda, Colombia. [4]Emerging Infectious Diseases and Tropical Medicine

Research Group. Instituto para la Investigación en Ciencias Biomédicas - Sci-Help, Pereira,

Risaralda, Colombia.[5]Grupo de Biotecnología-Productos Naturales, Facultad de Tecnología,

Universidad Tecnológica de Pereira, Colombia

*Corresponding author: Jaime A. Cardona-Ospina, Phone +57 311 339 5249, Fundación

Universitaria Autónoma de las Américas, Bloque B, Av. de las Américas #98-56 Sector

Belmonte, Pereira, Risaralda, Colombia, Postal Code: 660001, e-mail:

jaime.cardona@uam.edu.co

Words: 1991 | Abstract: 308 | Figures: 3 | Tables: 1 | Supplementary Tables: 2

Abstract:

Introduction: SARS-CoV-2 infection has represented the one of the largest challenges for humanity. This virus was first detected in Latin America and the Caribbean (LAC) in Brazil in February 26, 2020 and it has revealed important gaps in infectious disease surveillance that must be covered. Phylodynamic analysis is a tool that can help to monitor and adapt traditional surveillance measures in order to cover those. Therefore, this work aims to contrast data driven from epidemiologic surveillance in LAC with parameters inferred from phylodynamic analysis of reported genomes of SARS-CoV-2 across different LAC countries **Methods:** We obtained epidemiological data from daily reports provided by European Centre for Disease Prevention and Control up to 13th May, 2020. We estimated Effective Reproductive Number (Re) and calculated epidemic curves with exponential growth (EG) and maximum likelihood (ML) methods. SARS-CoV-2 phylodynamic in Latin-American was analyzed using sequences reported in GISAID for Central and South America up to May 13th 2020. Sequences were aligned, and ML phylogeny was constructed. Coalescent model Birth Death SIR (serial) was run, and SIR trajectories from the birth-death SIR model were plotted. **Results:** A total of 404,448 cases were reported up to 13th May 2020. Overall reproduction number for Latin America, estimated through the EG and ML methods, were 1.424 (IC95% 1.422 to 1.426) and 1.305 (IC95% 1.299 to 1.311) respectively. Phylodynamic analysis for Latin America showed an overall Re of 1.27 (IC95% 1.07 to 1.49). We did not find statistically significant differences between epidemiological and phylodynamic data at the cut-off time, except for Brazil. **Discussion:** Our results support that epidemiological and genomic surveillance are two complementary approaches. Evidence suggests that even with a low number of sequences proper estimations of Re could be performed. We suggest that countries, especially developing

46   countries, should consider to add genomic surveillance to their systems for monitoring and

47   adapting epidemiological surveillance of SARS-CoV-2.

49   **Keywords:**

50   SARS-CoV-2, COVID-19, Phylodynamic, Epidemiology, Latin America

Introduction:

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus - 2) infection, called COVID-19, has represented one of the largest challenge for humanity, and has revealed the need for better, more accurate, and more expedite surveillance tools, for improving infectious disease control. SARS-CoV-2 transmissibility across the world has varied widely[1], apparently related with control measures, and intensity of disease surveillance. COVID-19 has revealed deep gaps in our society derived from social inequalities, and has showed the importance of solid evidence based decision making, the need to strength our healthcare systems and to improve infectious disease surveillance.

After the emergence of SARS-CoV-2 in Wuhan, central China in December 2019, COVID-19 rapidly spread across the world, and was first reported in Latin America and the Caribbean (LAC) on February 26, 2020 in Brazil[1]. This virus belongs to the genus Betacoronavirus of the Coronaviridae family, it has a (+) ssRNA genome of approximately 29,903bp, and the genomic information accumulated through its evolution has been used for tracking its molecular relatedness with other coronaviruses, and for estimating transmission networks, epidemic size, and effective reproduction number (Re) [2-5].

In this context, current available phylogenetic methods can serve as tool for improving infectious disease surveillance. Development of the coalescent theory allows to infer from evolutionary analysis the epidemiologic behavior of a pathogen, especial those rapidly evolving, like RNA virus[6-8]. These analysis can enhance disease surveillance efforts, provide additional data for adapting disease surveillance strategies, and can help to assess

effectiveness of implemented surveillance as well as to estimate the Re, generation time,

and epidemic size [9, 10]. This work aims to contrast data driven from epidemiologic

surveillance in LAC with parameters inferred from phylodynamic analysis of reported

genomes of SARS-CoV-2 across different LAC countries.

Materials and Methods

Epidemiological data source

In order to contrast phylodynamic inference with COVID-19 epidemiological surveillance

data , we obtained data published by the European Centre for Disease Prevention and Control

[1] until 13th May, 2020. Countries were filtered by continent and only countries belonging to

Latin America and the Caribbean region were included. Incident cases and dates of reporting

were obtained, as well as fatal cases. We calculated Case Fatality Rates (CFR) = number of

reported deaths/number of total cases) X 100, and estimated Re and epidemiologic curves

using exponential growth and maximum likelihood methods[11-13].

Estimation of Effective Reproduction Numbers

In order to estimate Re, we estimated the Generation time (GT) using the R package R0 [11].

The distribution of the generation time, considered as the time between a primary infected

case and a secondary case, was estimated by Maximun Likelihood using the serial time

between infectee/infector pairs published by He et al, 2020 [11, 14]. Then, Re at the beginning

of the epidemic, and its evolution through time were estimated using Exponential Growth

(EG) and Maximum Likelihood (ML) methods [12, 13, 15]. The time period over which growth

is exponential was estimated using the deviance R-squared statistic over a range of possible

time periods [11].

Dataset for phylodynamic analysis

In order to investigate de SARS-CoV-2 phylodynamic in Latin-American, we search for

sequences reported in GISAID [16] for Central and South America up to May 13th 2020. We

choose only whole genome sequences (>29,900) of the virus with high coverage, and more

than 95% of nucleotide base resolved. We conserved identical sequences with different

sampling dates and different location and discard identical sequences with same sampling

date between countries. Accession IDs, sampling dates and locations of the sequences were

obtained, as well as clinical metadata when available. We also generated subgroup datasets

for each country reporting at least five sequences.

Phylogenetic analyses

Sequences were aligned using MAFFT software v7.450 [17] and visually inspected and edited

using Bioedit v7.0.5.3. To assess the recombination for the dataset, we employed the

pairwise homoplasy index (PHI) test using SplitsTree v4.15.1[18]. Nucleotide substitution

model for the alignment was inferred according to the corrected Akaike information

criterion (AICc) in jModelTest v2.1.10 [19]. Maximun Likelihood (ML) phylogeny was

constructed using PhyML software v3.1[20] and the tree was visualized and edited with

FigTree software v1.8.

Coalescent analyses

For LAC and each country data set, coalescent model Birth Death SIR (serial) [21] was run

with *Phylodynamics* package in BEAST v2.6.2.0 [22]. Priors were introduced with BEAUti

and all data sets were run with the same prior distribution and value for Molecular clock

rate (1.0 (estimated)), Become Uninfectious Rate (Normal (mean=37.0, sigma =1.3)) and

Reproductive Number (Log-normal (mean log=0,0, sd log =1.2)). Markov chain Monte

Carlo (MCMC) runs of 80 million states sampling every 8,000 steps were computed. The

convergence of MCMC chains was checked using Tracer v.1.7.1[23], ensuring that the

effective sample size (ESS) values were greater than 300 for each parameter estimated. For

LAC data set, the maximum clade credibility (MCC) trees were obtained from the tree

posterior distribution using TreeAnnotator after 10% burn-in [23]. To plot SIR trajectories

from the birth-death SIR model we used NELSI package for R.

Sensitivity analysis

We conducted a sensitivity analysis computing the R-squared statistic over a

range of possible time periods for exponential growth (begin between days 1 to 39, and

ending between days 40 to 79), selecting the best fit for EG and ML analysis. In order to

assess the effect of GT distribution variation on Re estimation, we computed the

reproduction ratio over a range of chosen generation time distributions with mean between

1 to 14 days, assuming fixed standard deviation, and using ML method.

Results

A total of 404,448 cases were reported up to 13th May 2020, with 23,153 deaths (overall

CFR 5.72%). The countries with most cases were: Brazil (177,589 cases), Peru (72,059

cases), Mexico (38,324 cases), Chile (31,721 cases) and Ecuador (30,419 cases), while the

countries with the highest CFR were Saint Maarteen (19.48%), British Virgin Islands

(14.29%), Antigua and Barbuda (12%), Bahamas (11.83%) and Belize (11.11%), Table 1.

A total of 124 genomic sequences were retrieved from GISAID library [16], and after quality

clearance 76 genomic sequences, from 6 countries, were finally included for analysis

(**Supplementary Table 1**).

Overall reproduction number for Latin America, estimated through the EG and ML

methods, were 1.424 (IC95% 1.422 to 1.426) and 1.305 (IC95% 1.299 to 1.311)

respectively. The epidemic curve and time dependent analysis is showed in Figure 1. The

portion of the epidemic curve that best fitted exponential growth was estimated between

2020-02-26 and 2020-04-11 (first 45 days), with a Growth Rate of 11.91%, and a Re of

1.95 (IC95% 1.94 to 1.95) and 1.74351(IC95% 1.72 to 1.77) through EG and ML method,

respectively. Sensitivity analysis showed that Re remained within the 95%IC only for a

small choice of time windows Figure 1c, and that varied significantly across different GT

distributions (data not shown).

For Latin American ML phylogenetic reconstruction, the GTR+I+G was the best model of

nucleotide substitution for the data set (substitution rates for every data set is showed in

Supplementary Table 2). The PHI test did not found statistically significant evidence for

recombination (p = 0.01381). The ML tree (Figure 2) shown a star-like topology in which

the external arms are longer than the internal without evidence of structure or space related

distribution. Phylodynamic analysis for Latin America showed an overall Re of 1.27

(IC95% 1.07 to 1.49).

To properly contrast observed epidemiologic curves with phylodynamic inferences, we

performed subgroup analysis including only countries with at least five reported genomic

sequences, and estimating epidemiological observed Re up to the date of the last available

genomic sequence. Therefore, only four countries were finally included in the subgroup

analysis; Brazil (last reported sequence 03-26-2020, 30 days since first case notification),

Argentina (last reported sequence 04-19-2020, 44 days since first case notification), Chile

(last reported sequence 03-08-2020, 5 days after first case notification) and Costa Rica (last

reported sequence 03-25-2020, 18 days after first case notification). Epidemic curves and

SIR trajectories for each country are showed in Figure 3.

Posterior summary of epidemiological and evolutionary parameters are shown in Table 1.

When contrasting observed and inferred Re, we did not find statistically significant

differences between epidemiological and phylodynamic data at the cut-off time, except for

Brazil. Phylodynamic inference showed an Re for Argentina of 1.48 (IC95% 1.19 to 1.79)

contrasted with epidemiological Re estimated using EG of 1.39 (IC95%1.36 to 1.41) and

ML of 1.29 (IC95% 1.22 to 1.36). For Brazil showed a Re of 1.59 (IC95% 1.18 to 2.03)

contrasted with epidemiological Re estimated using EG of 3.03 (IC95% 2.92 to 3.15) and

ML of 2.51 (IC95% 2.37 to 2.65). For Costa Rica showed an Re of 2.33 (IC95% 1.02 to

3.78) contrasted with epidemiological Re estimated using EG of 2.14 (IC95% 1.84 to 2.48)

and ML of 2.09 (IC95% 1.69 to 2.56). And for Chile showed 2.69 (IC95% 1.15 to 4.41)

contrasted with epidemiological Re estimated using EG of 0.02 (IC95% 0.00 to 4.51) and

ML of 2.87 (IC95% 0.48 to 8.86). Additionally, we found important differences in the

number of reported versus inferred prevalent cases. Phylodynamic analysis showed a total

of 119 cases in Brazil, 245 cases in Argentina, 58 in Chile, and 61 cases in Costa Rica,

contrasted with a total of 2,433; 2,828; 5; 177 cases reported in each country respectively,

at the time of cut-off.

Discussion:

Our results revealed an overall agreement between epidemiological observed data and

photodynamically inferred Re, even for Costa Rica with only five reported genomic

sequences up to the date of cut off. However, observed and inferred Re for Brazil varied

widely among methods. Sensitivity analysis revealed that for obtention of overlapping Re

IC95%, GT mean should be between 4.29 and 5.62 (SD range between 4.12 and 7.02),

hence suggesting that likely transmission dynamics in this country could be different to

those previously reported [14], while the fact that observed and inferred Re were not different

among the other countries supports that transmission dynamics are similar to those reported

by He et al, 2020[14].

However, SIR trajectories revealed disagreement in terms of incident cases, total cases and

recovered cases. For some countries, recovered cases were higher than incident cases, like

for example Argentina and Brazil (Figure 3). We hypothesize that this disagreement could

be related with the real origin of the sequences reported from each country and the real date

of SARS-CoV-2 introduction. Since most of sequences available when the analysis was

performed were reported at the beginning of the epidemic in each country, it is possible that

genomic data did not reveal internal transmission networks but external transmission

networks from imported cases. This could be supported on the analysis of ML phylogenetic

tree, which did not reveal a space related distribution.

Moreover, SIR trajectories analysis for some countries inferred recovered cases above

infected cases. This disagreement with the observed epidemiological data is interpreted by

our group as a likely introduction before the epidemiological reported date. In order to

support this hypothesis, we are currently performing Time to Most Recent Ancestor

Analysis (TMRA) for each country, including new reported sequences for LAC, which up

to May 22, 2020 have increased to 326 (complete and with high coverage).

Finally, our results support that epidemiological and genomic surveillance are two

complementary approaches for analysis of transmission and epidemiological patterns.

Overall Re estimation for LAC through phylodynamic analysis showed good agreement

with observed Re through epidemiological surveillance even when sequences were not

available from every country. Evidence suggests that even with a low number of sequences,

proper estimations of Re could be performed. This could provide important insights,

especially at the beginning of an epidemic when epidemiological surveillance systems are

adjusting follow-up and control measures. At the same time, we found that the lack of

clinical and epidemiological metadata for reported sequences difficult making

phylodynamic inferences. We suggest that countries, especially developing countries,

should consider to add genomic surveillance to their systems for monitoring and adapting

epidemiological surveillance of SARS-CoV-2.

Acknowledgements:

We would like to acknowledge Grupo de Investigación SIRIUS, Facultad de Ingenierias,

Universidad Tecnológica de Pereira, for providing resources for performing high

performance computational analysis. We also want to acknowledge the laboratories that

have contributed publicly available genomes via GISAID in Latin America.

References

1.   European Centre for Disease Prevention and Control. Geographic distribution of

COVID-19 cases worldwide. European Centre for Disease Prevention and Control,, 2020.

2.   Benvenuto D, Giovanetti M, Salemi M, Prosperi M, De Flora C, Junior Alcantara

LC, et al. The global spread of 2019-nCoV: a molecular evolutionary analysis. Pathog Glob

Health 2020; 114:64-7.

3.   Dellicour S, Durkin K, Hong SL, Vanmechelen B, Martí-Carreras J, Gill MS, et al.

A phylodynamic workflow to rapidly gain insights into the dispersal history and dynamics

of SARS-CoV-2 lineages. bioRxiv 2020.

4.   Li J, Li Z, Cui X, Wu C. Bayesian phylodynamic inference on the temporal

evolution and global transmission of SARS-CoV-2. J Infect 2020.

5.   Scire J, Vaughan TG, Stadler T. Phylodynamic analyses based on 93 genomes.

2020.

6.   Holmes EC. Evolutionary history and phylogeography of human viruses. Annu Rev

Microbiol 2008; 62:307-28.

7.   Pybus OG, Rambaut A, Harvey PH. An integrated framework for the inference of

viral population history from reconstructed genealogies. Genetics 2000; 155:1429-37.

8.   Volz EM, Koelle K, Bedford T. Viral phylodynamics. PLoS Comput Biol 2013;

9:e1002947.

9.   Grenfell BT, Pybus OG, Gog JR, Wood JL, Daly JM, Mumford JA, et al. Unifying

the epidemiological and evolutionary dynamics of pathogens. Science 2004; 303:327-32.

10.   Rife BD, Mavian C, Chen X, Ciccozzi M, Salemi M, Min J, et al. Phylodynamic

applications in 21(st) century global infectious disease research. Glob Health Res Policy

2017; 2:13-.

11.   Obadia T, Haneef R, Boelle PY. The R0 package: a toolbox to estimate

reproduction numbers for epidemic outbreaks. BMC Med Inform Decis Mak 2012; 12:147.

12.   Wallinga J, Lipsitch M. How generation intervals shape the relationship between

growth rates and reproductive numbers. Proc Biol Sci 2007; 274:599-604.

13.   White LF, Pagano M. A likelihood-based method for real-time estimation of the

serial interval and reproductive number of an epidemic. Stat Med 2008; 27:2999-3016.

14.   He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral

shedding and transmissibility of COVID-19. Nat Med 2020; 26:672-5.

15.   Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory

syndrome reveal similar impacts of control measures. Am J Epidemiol 2004; 160:509-16.

16.   Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative

contribution to global health. Glob Chall 2017; 1:33-46.

17.   Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7:

improvements in performance and usability. Mol Biol Evol 2013; 30:772-80.

18.   Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies.

Mol Biol Evol 2006; 23:254-67.

19.   Darriba D, Taboada GL, Doallo R, Posada D. jModelTest 2: more models, new

heuristics and parallel computing. Nat Methods 2012; 9:772.

20.   Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New

algorithms and methods to estimate maximum-likelihood phylogenies: assessing the

performance of PhyML 3.0. Syst Biol 2010; 59:307-21.

21.   Kuhnert D, Stadler T, Vaughan TG, Drummond AJ. Simultaneous reconstruction of

evolutionary history and epidemiological dynamics from viral sequences with the birth-

death SIR model. J R Soc Interface 2014; 11:20131106.

22.   Bouckaert R, Vaughan TG, Barido-Sottani J, Duchêne S, Fourment M,

Gavryushkina A, et al. BEAST 2.5: An advanced software platform for Bayesian

evolutionary analysis. PLoS computational biology 2019; 15:e1006650.

23.   Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior Summarization

in Bayesian Phylogenetics Using Tracer 1.7. Syst Biol 2018; 67:901-4.

Figure 1. Maximum likelihood phylogenetic relationships between sequences of Latin
 America data set. Branch lengths estimated as nucleotide substitutions per site.

342   Figure 2. Epidemic curve (A), Time-dependent analysis of Re (B) in Latin America up to

343   May 13th, 2020, and Sensitivity analysis of exponential growth of epidemic curve (C).

345 Figure 3. SIR trajectories (A), and epidemic curves (B) for countries with at least five

346 reported genomic sequences. The line corresponds to the epidemic curve estimated through

347 ML method and the dots to incident cases up to the date of the last reported sequence.

369 **Table 1**. Posterior summary of epidemiological and evolutionary parameters.
370

	Molecular clock rate	95% HPD	Become Uninfectious Rate	95% HPD	Reproductive Number	95% HPD
Latin America	0.00014	0.00011-0.00018	36.88	34.38-39.39	1.22	1.0446-1.4156
Argentina	0.00013	0.0006-0.002	36.86	34.25-39.25	1.48	1.022-3.78
Brazil	0.00028	0.00018-0.00038	36.97	43.44-39.50	1.59	1.1792-2.0277
Chile	0.00044	0.00006-0.00094	36.97	34.47-39.57	2.69	1.1455-4.4077
Costa Rica	0.00058	0.00018-0.0010	36.93	34.49-39.58	2.32	1.022-3.78

372 **Supplementary Table 1**. Substitution model and parameters used to run each data set with
373 BEAST.
374

Region/Country	Model	Substitutions rates	Parameters
Latin America	Model = GTR+I+G	R(a) [AC] = 0.3454 R(b) [AG] = 0.8055 R(c) [AT] = 0.1965 R(d) [CG] = 0.3182 R(e) [CT] = 2.6714 R(f) [GT] = 1.0000	p-inv = 0.8980 gamma category count = 0 Frequencies = empirical
Argentina	Model = GTR+I	R(a) [AC] = 0.0100 R(b) [AG] = 1.4896 R(c) [AT] = 0.0829 R(d) [CG] = 0.4389 R(e) [CT] = 3.9014 R(f) [GT] = 1.0000	p-inv = 0.7800 gamma category count = 0 Frequencies = empirical
Brazil	Model = GTR+I+G	R(a) [AC] = 0.5540 R(b) [AG] = 0.7814 R(c) [AT] = 0.2557 R(d) [CG] = 0.4662 R(e) [CT] = 2.6314 R(f) [GT] = 1.0000	p-inv = 0.9540 gamma category count = 0 Frequencies = empirical
Chile	GTR	R(a) [AC] = 0.0216 R(b) [AG] = 0.9991 R(c) [AT] = 0.2091 R(d) [CG] = 0.5565 R(e) [CT] = 3.7915 R(f) [GT] = 1.0000	p-inv = 0.0 gamma category count = 0 Frequencies = empirical
Costa Rica	HKY	Estimate	kappa = estimate

375
376

 Supplementary Table 2. Genomic sequences with dates, countries and accession ID
 included for phylodynamic analysis.

Accession ID	Sampling date	Country
hCoV-19/Argentina/C121/2020|EPI_ISL_420600|2020-03-07	07/03/2020	**Argentina**
hCoV-19/Argentina/C1374/2020|EPI_ISL_420599|2020-03-18	18/03/2020	**Argentina**
hCoV-19/Argentina/C3013/2020|EPI_ISL_420598|2020-03-22	22/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A001/2020|EPI_ISL_430793|2020-03-01	01/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A004/2020|EPI_ISL_430796|2020-03-27	27/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A005/2020|EPI_ISL_430797|2020-03-27	27/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A006/2020|EPI_ISL_430798|2020-03-28	28/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A007/2020|EPI_ISL_430799|2020-03-30	30/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A009/2020|EPI_ISL_430801|2020-03-31	31/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A011/2020|EPI_ISL_430802|2020-03-31	31/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A012/2020|EPI_ISL_430803|2020-04-01	01/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A013/2020|EPI_ISL_430804|2020-04-01	01/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A014/2020|EPI_ISL_430805|2020-04-01	01/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A016/2020|EPI_ISL_430807|2020-04-02	02/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A017/2020|EPI_ISL_430808|2020-04-03	03/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A018/2020|EPI_ISL_430809|2020-04-04	04/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A019/2020|EPI_ISL_430810|2020-04-07	07/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A020/2020|EPI_ISL_430811|2020-04-11	11/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A021/2020|EPI_ISL_430812|2020-04-11	11/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A023/2020|EPI_ISL_430814|2020-04-17	17/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A024/2020|EPI_ISL_430815|2020-04-18	18/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A025/2020|EPI_ISL_430816|2020-04-18	18/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A026/2020|EPI_ISL_430817|2020-04-18	18/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A027/2020|EPI_ISL_430818|2020-04-19	19/04/2020	**Argentina**
hCoV-19/Brazil/SPBR-01/2020|EPI_ISL_412964|2020-02-25	25/02/2020	**Brazil**
hCoV-19/Brazil/SPBR-06/2020|EPI_ISL_414015|2020-02-29	29/02/2020	**Brazil**
hCoV-19/Brazil/SPBR-09/2020|EPI_ISL_416031|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/RJ-314/2020|EPI_ISL_414045|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/CV42/2020|EPI_ISL_429695|2020-03-20	20/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-03/2020|EPI_ISL_414014|2020-03-02	02/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-04/2020|EPI_ISL_414017|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-07/2020|EPI_ISL_416028|2020-03-03	03/03/2020	**Brazil**
hCoV-19/Brazil/RJ-477/2020|EPI_ISL_427300|2020-03-11	11/03/2020	**Brazil**
hCoV-19/Brazil/RJ-477i/2020|EPI_ISL_427301|2020-03-11	11/03/2020	**Brazil**
hCoV-19/Brazil/DFBR-0001/2020|EPI_ISL_426580|2020-03-1	13/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-08/2020|EPI_ISL_416029|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-13/2020|EPI_ISL_416035|2020-03-05	05/03/2020	**Brazil**
hCoV-19/Brazil/BA-510/2020|EPI_ISL_427293|2020-03-06	06/03/2020	**Brazil**

hCoV-19/Brazil/SPBR-12/2020|EPI_ISL_416034|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/DF-615i/2020|EPI_ISL_427294|2020-03-13	13/03/2020	**Brazil**
hCoV-19/Brazil/DF-862/2020|EPI_ISL_427297|2020-03-23	23/03/2020	**Brazil**
hCoV-19/Brazil/DF-891/2020|EPI_ISL_427298|2020-03-22	22/03/2020	**Brazil**
hCoV-19/Brazil/RJ-763/2020|EPI_ISL_427302|2020-03-20	20/03/2020	**Brazil**
hCoV-19/Brazil/DF-861/2020|EPI_ISL_427296|2020-03-23	23/03/2020	**Brazil**
hCoV-19/Brazil/RJ-818/2020|EPI_ISL_427303|2020-03-25	25/03/2020	**Brazil**
hCoV-19/Brazil/RJ-872/2020|EPI_ISL_427304|2020-03-26	26/03/2020	**Brazil**
hCoV-19/Brazil/AL-837/2020|EPI_ISL_427292|2020-03-18	18/03/2020	**Brazil**
hCoV-19/Brazil/CV16/2020|EPI_ISL_429676|2020-03-16	16/03/2020	**Brazil**
hCoV-19/Brazil/SC-769/2020|EPI_ISL_427306|2020-03-10	10/03/2020	**Brazil**
hCoV-19/Brazil/CV4/2020|EPI_ISL_429667|2020-03-09	09/03/2020	**Brazil**
hCoV-19/Brazil/CV6/2020|EPI_ISL_429669|2020-03-13	13/03/2020	**Brazil**
hCoV-19/Brazil/CV21/2020|EPI_ISL_429681|2020-03-16	16/03/2020	**Brazil**
hCoV-19/Brazil/CV32/2020|EPI_ISL_429688|2020-03-17	17/03/2020	**Brazil**
hCoV-19/Brazil/CV31/2020|EPI_ISL_429687|2020-03-17	17/03/2020	**Brazil**
hCoV-19/Brazil/BA-312/2020|EPI_ISL_415105|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-02/2020|EPI_ISL_413016|2020-02-28	28/02/2020	**Brazil**
hCoV-19/Brazil/SPBR-10/2020|EPI_ISL_416032|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/ES-225/2020|EPI_ISL_415128|2020-02-29	29/02/2020	**Brazil**
hCoV-19/Brazil/SC-766/2020|EPI_ISL_427305|2020-03-10	10/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-11/2020|EPI_ISL_416033|2020-03-03	03/03/2020	**Brazil**
hCoV-19/Brazil/RJ-352/2020|EPI_ISL_427299|2020-03-05	05/03/2020	**Brazil**
hCoV-19/Brazil/AMBR-02/2020|EPI_ISL_417034|2020-03-16	16/03/2020	**Brazil**
hCoV-19/Chile/Santiago-2/2020|EPI_ISL_414580|2020-03-05	05/03/2020	**Chile**
hCoV-19/Chile/Talca-1/2020|EPI_ISL_414577|2020-03-02	02/03/2020	**Chile**
hCoV-19/Chile/Talca-2/2020|EPI_ISL_414578|2020-03-04	04/03/2020	**Chile**
hCoV-19/Chile/Santiago-1/2020|EPI_ISL_414579|2020-03-03	03/03/2020	**Chile**
hCoV-19/Chile/Santiago_op2d1/2020|EPI_ISL_415658|2020-03-06	06/03/2020	**Chile**
hCoV-19/Chile/Santiago_op3d1/2020|EPI_ISL_415660|2020-03-07	07/03/2020	**Chile**
hCoV-19/Chile/Santiago_op4d1/2020|EPI_ISL_415661|2020-03-08	08/03/2020	**Chile**
hCoV-19/Colombia/Antioquia79256/2020|EPI_ISL_417924|2020-03-11	11/03/2020	**Colombia**
hCoV-19/Costa Rica/06/2020|EPI_ISL_434539|2020-03-25	25/03/2020	**Costa Rica**
hCoV-19/Costa Rica/02/2020|EPI_ISL_434535|2020-03-16	16/03/2020	**Costa Rica**
hCoV-19/Costa Rica/04/2020|EPI_ISL_434540|2020-03-18	18/03/2020	**Costa Rica**
hCoV-19/Costa Rica/05/2020|EPI_ISL_434538|2020-03-20	20/03/2020	**Costa Rica**
hCoV-19/Costa Rica/01/2020|EPI_ISL_434533|2020-03-16	16/03/2020	**Costa Rica**
hCoV-19/Peru/010/2020|EPI_ISL_415787|2020-03-10	10/03/2020	**Peru**

382